Paula L. McClean
About
In The Last Decade
Paula L. McClean
54 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Physiology 1.6k
- Endocrinology, Diabetes and Metabolism 1.6k
- Molecular Biology 1.2k
- Cellular and Molecular Neuroscience 889
- Surgery 690
Countries citing papers authored by Paula L. McClean
This map shows the geographic impact of Paula L. McClean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula L. McClean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula L. McClean more than expected).
Fields of papers citing papers by Paula L. McClean
This network shows the impact of papers produced by Paula L. McClean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula L. McClean. The network helps show where Paula L. McClean may publish in the future.
Co-authorship network of co-authors of Paula L. McClean
This figure shows the co-authorship network connecting the top 25 collaborators of Paula L. McClean. A scholar is included among the top collaborators of Paula L. McClean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula L. McClean. Paula L. McClean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 4 | |
| 3 | 22 | |
| 4 | 66 | |
| 5 | Development of a computer-based clinical decision support tool for identifying individuals with different levels of cognitive impairment | 1 |
| 6 | 65 | |
| 7 | 150 | |
| 8 | 73 | |
| 9 | 142 | |
| 10 | The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease breakdown → | 583 |
| 11 | LIRAGLUTIDE, A NOVEL GLP-1 ANALOGUE, PREVENTS THE IMPAIRMENT OF LEARNING AND LTP AND PLAQUE FORMATION IN AN APP/PS-1 MOUSE MODEL OF ALZHEIMER'S DISEASE | 1 |
| 12 | 149 | |
| 13 | Novel GLP-1 analogues cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease | 6 |
| 14 | 161 | |
| 15 | 16 | |
| 16 | 119 | |
| 17 | 88 | |
| 18 | 19 | |
| 19 | 2 | |
| 20 | Successful treatment with oral mannose of a patient with congenital disorder of glycosylation Ib (CDG Ib) | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.